Open company graph database — free web & API
Login

De Western Therapeutics Research Institute Inc.

株式会社デ・ウエスタン・セラピテクス研究所De Western Therapitechs Laboratory Inc.AliasDe Western Therapeutics Research Institute, Inc.Alias
Ticker
Listed market
TYO
Country
Japan
Employees (consolidated)
19
Related companies
2
§01

Basic information

BASIC
Head office
18-11, Nishiki 1-chome, Naka-ku, Nagoya, Aichi Prefecture, Japan
Chief executive
Yuki Hidaka
Capital
697,000,000  (6 100 million)
Employees (non-consolidated)
19 people
Employees (consolidated)
19 people
Start date
1999-02-01
End date
§02

Websites

1 DOMAINS
§03

Business

1
Pharmaceutical research and development
§04

Related companies

2 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
Japan Innovation Pharma Co., Ltd.
Group
Rohto Pharmaceutical Co., Ltd.
Group
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

62 EVENTS

Established the De Western Therapeutics Research Institute Ltd. in Nagoya, Aichi Prefecture, for pharmaceutical research and development (capital 5,000 thousand yen).Sources

Established D.Western Therapeutics Institute, Inc. in Nagoya, Aichi Prefecture for the purpose of conducting pharmaceutical research and development (five million yen capitalization).Sources

Signed development and implementation agreements with Kowa Co., Ltd. for K-134 (occlusive atherosclerosis) and K-115 (glaucoma/ocular hypertension).Sources

Signed a development and implementation agreement with Kowa Co., Ltd. for K-115, a drug for treating glaucoma.Sources

Converted from a limited company to a corporation (capital 10,000 thousand yen).Sources

Changed from a limited company to a joint-stock corporation (10 million yen capitalization).Sources

Entered a joint research agreement with Mie University, a national university corporation, and established the "Clinical Drug Discovery Research Course" within the university.Sources

Entered into an industry-academia-government collaboration agreement with Mie University Faculty of Medicine for joint research, and jointly established Institute of Human Research Promotion and Drug Development at the University.Sources

Listed shares on the JASDAQ NEO (now Tokyo Stock Exchange Growth Market).Sources

Listed on JASDAQ Securities Exchange NEO Market (now Tokyo Stock Exchange Growth market).Sources

Signed a contract granting re-implementation rights for the development, manufacturing, use, and sale of H-1129 (glaucoma/ocular hypertension) in Japan with Wakimoto Pharmaceutical Co., Ltd.Sources

Signed a contract granting exclusive implementation rights with re-implementation license for the development, manufacturing, use, and sale of H-1129 (glaucoma and ocular hypertension) in Japan by Wakimoto Pharmaceutical Co., Ltd.Sources

Applied for domestic manufacturing and sales approval of K-115 (glaucoma/ocular hypertension).Sources

Obtained domestic manufacturing and sales approval for K-115 (product name: Granatac® eye drops 0.4%, generic name: Ripazil hydrochloride hydrate) for glaucoma/ocular hypertension.Sources

Domestic launch of Granatac® eye drops 0.4% (development code: K-115) for glaucoma/ocular hypertension.Sources

GLANATEC® ophthalmic solution 0.4% (generic name: Ripasudil hydrochloride hydrate, K-115) for glaucoma launched in Japan.Sources

Signed an introduction agreement to obtain exclusive implementation rights for an ophthalmic therapeutic agent in Japan (development code: DW-1001).Sources

Signed an in-licensing agreement to acquire exclusive Japan license for an ophthalmic drug (DW-1001).Sources

Made Nihon Innovation Pharmaceuticals Inc. a consolidated subsidiary.Sources

Made Japan Innovative Therapeutics Inc. a consolidated subsidiary.Sources

Acquired the business related to an ophthalmic surgical adjunct containing BBG250 (development code: DW-1002).Sources

Received transfer of business related to an ophthalmic surgical adjuvant (DW-1002).Sources

Commenced Phase I/early Phase II clinical trials in the United States for H-1337 (glaucoma/ocular hypertension), our first in-house developed product.Sources

Initiatied Phase I/IIa clinical trials of glaucoma treatment (H-1337), DWTI’s first in-house developed product, in the U.S.Sources

Signed a joint research and license agreement with Glaukos Corporation (USA) for glaucoma treatment products.Sources

Signed a joint research and licensing agreement with U.S.-based Glaukos Corporation for glaucoma drugs.Sources

Completed Phase I/early Phase II clinical trials in the United States for H-1337 (glaucoma/ocular hypertension).Sources

Phase I/IIa clinical trials of H-1337 glaucoma treatment completed in the U.S.Sources

Obtained import approval for Granatac® eye drops 0.4% (development code: K-115) for glaucoma/ocular hypertension in South Korea.Sources

Submitted an IND application for a Phase II clinical trial in the United States targeting Fuchs endothelial corneal dystrophy with Ripazil hydrochloride hydrate (development code: K-321).Sources

Submitted an Investigational New Drug (IND) application for Phase II clinical trials in the U.S. of Ripasudil hydrochloride hydrate as treatment for Fuchs endothelial corneal dystrophy (K-321).Sources

Discontinued development of H-1129 (glaucoma/ocular hypertension).Sources

Signed a license agreement with Lotte Pharmaceutical Co., Ltd. granting exclusive implementation rights for DW-1001 in Japan.Sources

Signed an agreement with Rohto Pharmaceutical Co., Ltd., granting exclusive Japan license for ophthalmic drug DW-1001.Sources

Start of Phase III clinical trial in Japan for a combination glaucoma treatment (Ripasudil hydrochloride hydrate and Brimonidine tartrate).Sources

Phase III clinical trials began in Japan for a fixed combination drug for treating glaucoma (Ripasudil hydrochloride hydrate and Brimonidine tartrate [K-232]).Sources

U.S. launch of DW-1002 (product name: TissueBlue™) (inner limiting membrane staining) and signing of a joint development agreement with Medrex Co., Ltd. for the neuropathic pain drug DW-5LBT.Sources

Ophthalmic surgical adjuvant DW-1002 (TissueBlue™) launched in the U.S.Sources

U.S. approval application for DW-5LBT (postherpetic neuralgia).Sources

Signed a joint development agreement with MEDRx Co., Ltd. for DW-5LBT neuropathic pain treatment.Sources

Applied for approval of DW-5LBT neuropathic pain treatment in the U.S.Sources

Addition of target diseases (corneal disorders, retinal diseases) for joint research with Glaukos Corporation in the U.S. and signing of a new license agreement.Sources

Added new disease types (corneal and retinal disorders) for joint research with U.S.-based Glaukos, and signed a new licensing agreement.Sources

Canadian launch of DW-1002 (product name: TissueBlue™) (inner limiting membrane staining).Sources

Ophthalmic surgical adjuvant DW-1002 (TissueBlue™) launched in Canada.Sources

Domestic manufacturing and sales approval application for K-232 (glaucoma and ocular hypertension).Sources

Applied for approval of K-232 glaucoma and ocular hypertension in Japan.Sources

Start of Phase I clinical trial in Japan for DW-1001.Sources

Phase I clinical trials of DW-1001 began in Japan.Sources

Signed a joint development agreement with Actuare Co., Ltd. for the regenerative cell product DWR-2206 targeting vesicular keratitis.Sources

Signed a joint development agreement with ActualEyes Inc. for DWR-2206 regenerative cell therapy for bullous keratopathy.Sources

Phase III clinical trials of K-321 for Fuchs endothelial corneal dystrophy began in U.S.Sources

Initiated Phase III clinical trial of K-321 (Fuchs' corneal endothelial dystrophy) in the United States.Sources

Domestic launch of Gralla® combination eye drops (development code: K-232) (glaucoma and ocular hypertension) and start of Phase II late-stage U.S. clinical trial for H-1337 (glaucoma and ocular hypertension).Sources

GLA-ALPHA® combination ophthalmic solution (generic name: Ripasudil hydrochloride hydrate, brimonidine tartrate, K-232) for glaucoma and ocular hypertension launched in Japan.Sources

GLA-ALPHA® combination ophthalmic solution (generic name: Ripasudil hydrochloride hydrate, brimonidine tartrate, K-232) for glaucoma and ocular hypertension launched in Japan. Initiatied Phase IIb clinical trials of glaucoma treatment (H-1337).Sources

Start of global Phase III clinical trial for K-321 (Fuchs endothelial corneal dystrophy).Sources

Phase III clinical trials of K-321 for Fuchs endothelial corneal dystrophy began in Global.Sources

Start of Phase II clinical trial in Japan for DWR-2206 (vesicular keratitis).Sources

Phase II clinical trials of DWR-2206 for bullous keratopathy began in Japan.Sources

U.S. approval obtained for DW-5LBT (postherpetic neuralgia).Sources

Approved of DW-5LBT neuropathic pain treatment in the U.S.Sources

§07

News

0 ARTICLES

There is no news.

§08

Public records

GOV
National Tax Agency basic information5180001055013
Source: National Tax Agency Corporate Number Publication Site, basic three itemsSources
Trade name
株式会社デ・ウエスタン・セラピテクス研究所
Trade name (kana)
デウエスタンセラピテクスケンキュウジョ
Name in English
Corporation type
301
Address
〒460-0003 愛知県名古屋市中区錦1丁目18番11号
Postal code
4600003
Prefecture code
23
City code
106
Address outside Japan
Prefecture in English
City in English
Address outside Japan in English
Corporate number assignment date
2015-10-05
Update date
2023-04-18
Change date
2015-10-05
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
Latest record
1
Excluded from search
0
Processing type
01
Correction type
1
Trade name image ID
Address image ID
Sequence number
3614749
METI gBizINFO5180001055013
Source: gBizINFO (Ministry of Economy, Trade and Industry)Sources
Corporate number
5180001055013
Trade name
株式会社デ・ウエスタン・セラピテクス研究所
Trade name (kana)
デウエスタンセラピテクスケンキュウジョ
Trade name (alphabet)
Registry closure date
Reason for registry closure
Registered address
愛知県名古屋市中区錦1丁目18番11号
Postal code
4600003
Prefecture
愛知県
Prefecture code
23
City or district
名古屋市中区
City code
106
Street address
錦1丁目18番11号
Organisation type
301
Processing type
01
Correction type
1
Status
Representative
代表取締役社長  日高 有一
Capital
697340000
Employees
19
Employees (male)
Employees (female)
Business summary
Website URL
Year founded
Business category
Date established
Unified government qualification - grade
Unified government qualification - business items
Update date
2023-04-18
Key information
5180001055013
§09

Sources & updates

SOURCES
↑